AIGH Capital Management LLC Trims Holdings in Zevra Therapeutics, Inc. $ZVRA

AIGH Capital Management LLC decreased its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 36.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 918,893 shares of the company’s stock after selling 519,216 shares during the period. Zevra Therapeutics comprises approximately 3.6% of AIGH Capital Management LLC’s holdings, making the stock its 11th largest holding. AIGH Capital Management LLC’s holdings in Zevra Therapeutics were worth $8,095,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZVRA. Readystate Asset Management LP increased its stake in Zevra Therapeutics by 924.6% in the first quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after purchasing an additional 616,370 shares during the period. Woodline Partners LP increased its stake in Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares during the period. Velan Capital Investment Management LP increased its stake in Zevra Therapeutics by 121.7% in the first quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock worth $4,981,000 after purchasing an additional 365,000 shares during the period. Wellington Management Group LLP purchased a new stake in Zevra Therapeutics in the first quarter worth $1,052,000. Finally, Stonepine Capital Management LLC increased its stake in Zevra Therapeutics by 8.8% in the first quarter. Stonepine Capital Management LLC now owns 650,000 shares of the company’s stock worth $4,868,000 after purchasing an additional 52,300 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

ZVRA opened at $10.81 on Monday. The business’s 50-day moving average is $9.34 and its two-hundred day moving average is $9.21. Zevra Therapeutics, Inc. has a 1 year low of $6.19 and a 1 year high of $13.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. The firm has a market capitalization of $606.77 million, a PE ratio of -51.48 and a beta of 1.49.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($1.49). Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. The company had revenue of $25.88 million during the quarter, compared to analysts’ expectations of $22.49 million. Research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZVRA has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. JMP Securities cut their price target on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Cantor Fitzgerald raised their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Thursday, July 10th. Zacks Research lowered Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Finally, HC Wainwright started coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Insider Activity

In related news, Director John B. Bode bought 5,000 shares of the business’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the transaction, the chief executive officer owned 222,016 shares in the company, valued at $2,402,213.12. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.